Paratek Pharmaceuticals News

Keyword Search

Date Title  
Nov 06, 2018
Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
Nov 01, 2018
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 26, 2018
Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018
Oct 04, 2018
Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline
Oct 03, 2018
Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018
Oct 02, 2018
Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)
Oct 02, 2018
FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne
Oct 01, 2018
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 25, 2018
Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018
Sep 04, 2018
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)